Arovella Therapeutics Limited (ASX:ALA)
Australia · Delayed Price · Currency is AUD 0.1050
+0.0070 (7.14%)
Aug 1, 2025, 4:10 PM AEST
Arovella Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2020 |
Operating Revenue | 0.14 | 0.02 | 0.41 | 0.3 | 0.26 | 0.53 | Upgrade |
Other Revenue | 3.3 | 1.94 | 1.05 | - | 0.73 | 0.72 | Upgrade |
| 3.45 | 1.95 | 1.45 | 0.3 | 0.99 | 1.25 | Upgrade | |
Revenue Growth (YoY) | 75.02% | 34.20% | 391.75% | -70.11% | -20.91% | 0.05% | Upgrade |
Cost of Revenue | - | - | 0.2 | 0.21 | 0.24 | 0.22 | Upgrade |
Gross Profit | 3.45 | 1.95 | 1.25 | 0.09 | 0.75 | 1.03 | Upgrade |
Selling, General & Admin | 1.62 | 1.36 | 1.5 | 1.32 | 1.31 | 1.37 | Upgrade |
Research & Development | 5.65 | 6.74 | 3.98 | 2.6 | 0.71 | - | Upgrade |
Other Operating Expenses | 1.65 | 1.64 | 2.7 | 2.63 | 2 | 3.05 | Upgrade |
Operating Expenses | 10.01 | 10.83 | 9.88 | 7.69 | 4.7 | 5.09 | Upgrade |
Operating Income | -6.56 | -8.88 | -8.63 | -7.6 | -3.96 | -4.06 | Upgrade |
Interest Expense | - | - | -0 | -0.19 | -0.03 | -0.01 | Upgrade |
Interest & Investment Income | 0.31 | 0.14 | 0.03 | 0 | 0.01 | 0.04 | Upgrade |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.02 | -0 | -0.01 | -0.01 | Upgrade |
EBT Excluding Unusual Items | -6.26 | -8.75 | -8.62 | -7.79 | -3.98 | -4.04 | Upgrade |
Asset Writedown | - | - | -1.56 | -0.83 | -1.24 | -0.27 | Upgrade |
Other Unusual Items | - | - | - | - | 0.17 | 0.08 | Upgrade |
Pretax Income | -6.26 | -8.75 | -10.18 | -8.62 | -5.05 | -4.23 | Upgrade |
Earnings From Continuing Operations | -6.26 | -8.75 | -10.18 | -8.62 | -5.05 | -4.23 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | -5.7 | Upgrade |
Net Income to Company | -6.26 | -8.75 | -10.18 | -8.62 | -5.05 | -9.94 | Upgrade |
Net Income | -6.26 | -8.75 | -10.18 | -8.62 | -5.05 | -9.94 | Upgrade |
Net Income to Common | -6.26 | -8.75 | -10.18 | -8.62 | -5.05 | -9.94 | Upgrade |
Shares Outstanding (Basic) | 1,018 | 941 | 711 | 550 | 331 | 142 | Upgrade |
Shares Outstanding (Diluted) | 1,018 | 941 | 711 | 550 | 331 | 142 | Upgrade |
Shares Change (YoY) | 23.23% | 32.32% | 29.45% | 66.10% | 132.61% | 44.30% | Upgrade |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.07 | Upgrade |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.07 | Upgrade |
Free Cash Flow | -6.54 | -7.04 | -6.4 | -6.3 | -3.71 | -3.02 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | Upgrade |
Gross Margin | 100.00% | 100.00% | 86.01% | 30.00% | 75.29% | 82.05% | Upgrade |
Operating Margin | -190.25% | -454.69% | -593.40% | -2568.01% | -399.66% | -324.83% | Upgrade |
Profit Margin | -181.62% | -448.03% | -699.91% | -2914.23% | -509.99% | -793.94% | Upgrade |
Free Cash Flow Margin | -189.75% | -360.80% | -439.99% | -2130.85% | -374.92% | -241.71% | Upgrade |
EBITDA | -6.49 | -8.83 | -8.53 | -7.46 | -3.82 | -3.92 | Upgrade |
EBITDA Margin | -188.25% | - | - | - | - | - | Upgrade |
D&A For EBITDA | 0.07 | 0.04 | 0.1 | 0.14 | 0.14 | 0.15 | Upgrade |
EBIT | -6.56 | -8.88 | -8.63 | -7.6 | -3.96 | -4.06 | Upgrade |
EBIT Margin | -190.25% | - | - | - | - | - | Upgrade |
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.